BS_KPT2WPHW
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 3.876478318002628
- age_years
- 0.992
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.499
- PANCREAS_BETA_CELLS+0.426
- SPERMATOGENESIS+0.360
- HEDGEHOG_SIGNALING+0.247
- MYOGENESIS+0.244
- APICAL_SURFACE+0.194
- ESTROGEN_RESPONSE_LATE+0.129
- ESTROGEN_RESPONSE_EARLY+0.112
- BILE_ACID_METABOLISM+0.103
- APICAL_JUNCTION+0.089
Top 10 suppressed
- MYC_TARGETS_V1-0.637
- MYC_TARGETS_V2-0.617
- DNA_REPAIR-0.557
- E2F_TARGETS-0.553
- UNFOLDED_PROTEIN_RESPONSE-0.552
- INTERFERON_ALPHA_RESPONSE-0.546
- INTERFERON_GAMMA_RESPONSE-0.534
- PROTEIN_SECRETION-0.526
- G2M_CHECKPOINT-0.502
- OXIDATIVE_PHOSPHORYLATION-0.470
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_C7N3J4NW | high-grade glioma | — | 0.984 |
| 2 | BS_K5802F84 | pilocytic astrocytoma | — | 0.980 |
| 3 | BS_CQSAJ7BF | DNET | — | 0.976 |
| 4 | BS_92VDQ0NE | Ganglioglioma | — | 0.976 |
| 5 | BS_6MY8W3H0 | DNET | — | 0.975 |
| 6 | BS_SM8VQFPD | DNET | — | 0.965 |
| 7 | BS_3T6X4BPC | DNET | — | 0.963 |
| 8 | BS_QV51J756 | Ganglioglioma | — | 0.961 |
| 9 | BS_QC3XCE6X | low-grade glioma | — | 0.959 |
| 10 | BS_MF47B9ZW | Ganglioglioma | — | 0.958 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.499 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.426 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.360 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.247 | Inavolisib | — uncovered |
| MYOGENESIS | 0.244 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.194 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.129 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.112 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.103 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.089 | Inavolisib | — uncovered |
| COAGULATION | 0.035 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.021 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.005 | Inavolisib | — uncovered |